Catalyst Pharma Merger with Angelini Pharma Gets HSR Clearance

Catalyst Pharmaceuticals, Inc. announced that the U.S. Federal Trade Commission (FTC) granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for its merger with Angelini Pharma S.p.A. This clearance, received on June 16, 2026, removes a significant condition for the merger. The closing of the merger, which was initially announced on May 6, 2026, is now primarily subject to the adoption of the Merger Agreement by Catalyst's shareholders and other customary closing conditions. The parties anticipate the transactions to close in the third quarter of 2026.